Skip to main content
. 2009 Jun 18;106(27):11137–11142. doi: 10.1073/pnas.0900465106

Fig. 1.

Fig. 1.

Rapamycin reduces polyposis, mTORC1 signaling, and proliferation in Lkb1+/− polyps. (A) Top are images of whole stomach and duodenum and Bottom are images of the open stomachs (S) showing the exposed polyps (P) from Lkb1+/− mice treated with either vehicle (VEH) (i, iv) or rapamycin (RAPA) (ii, v) and Lkb1+/+ mice treated with vehicle (VEH) (iii, vi). (B) Immunohistochemical analysis of polyps from VEH- or RAPA-treated Lkb1+/− mice: H & E staining (i, ii), P-S6 staining (iii, iv), and Ki67 staining (v, vi). Results are representative of polyps from 5 mice of each treatment group. (C) A graph of the total polyp burden in Lkb1+/− mice treated with either VEH (○, n = 11) or RAPA (●, n = 10). The mean polyp burden for RAPA-treated mice (2.0 ± 1.2) was significantly reduced (∗, P = 0.00026; Student t test, 2 tail) compared with those mice treated with VEH (9.6 ± 5.5). (D) Average polyp number in VEH-treated mice (black bar, n = 11) or RAPA-treated mice (gray bar, n = 10). Only visible polyps between 1 and ≥5 mm were scored in both VEH- and RAPA-treated mice. The mean polyp number for RAPA-treated mice (2.8 ± 1.4) was significantly reduced (∗, P = 0.00022; Student t test, 2 tail) compared with VEH-treated mice (5.3 ± 1.8). (E) Average polyp size in VEH-treated mice (black bar, n = 11) or RAPA-treated mice (gray bar, n = 10). The mean polyp size in RAPA mice (1.2 ± 0.9) was significantly reduced (∗, P < 0.0001; Student t test, 2 tail) compared with VEH-treated mice (4.4 ± 0.8). (F) Average percentage of Ki67-positive epithelial cells in VEH-treated mice (black bar, n = 5) or RAP- treated mice (gray bar, n = 5). The mean percentage of Ki67-positive cells in RAPA mice (24.5 ± 6.1) was significantly reduced (∗, P < 0.0002; Student t test, 2 tail) compared with VEH-treated mice (59.7 ± 7.3).